Citation: S. Harder et al., DOSE-RESPONSE AND CONCENTRATION RESPONSE RELATIONSHIP OF APOMORPHINE IN PATIENTS WITH PARKINSONS-DISEASE AND END-OF-DOSE AKINESIA, International journal of clinical pharmacology and therapeutics, 36(7), 1998, pp. 355-362
Authors:
BAAS H
HARDER S
BURKLIN F
DEMISCH L
FISCHER PA
Citation: H. Baas et al., PHARMACODYNAMICS OF LEVODOPA COADMINISTERED WITH APOMORPHINE IN PARKINSONIAN-PATIENTS WITH END-OF-DOSE MOTOR FLUCTUATIONS, Clinical neuropharmacology, 21(2), 1998, pp. 86-92
Authors:
VODERHOLZER U
LAAKMANN G
BECKER U
HAAG C
BAGHAI T
RIEMANN D
DEMISCH L
Citation: U. Voderholzer et al., CIRCADIAN PROFILES OF MELATONIN IN MELANCHOLIC DEPRESSED-PATIENTS ANDHEALTHY-SUBJECTS IN RELATION TO CORTISOL SECRETION AND SLEEP, Psychiatry research, 71(3), 1997, pp. 151-161
Authors:
SIEKMEIER R
OMMERT S
BERGMANN S
DEMISCH L
JAROSS W
GROSS W
Citation: R. Siekmeier et al., INCREASED CONCENTRATIONS OF APOLIPOPROTEIN-E AND PROTEIN-TAU IN CEREBROSPINAL-FLUID OF PATIENTS WITH MULTIPLE-SCLEROSIS, Pflugers Archiv, 433(6), 1997, pp. 206-206
Citation: S. Harder et al., PK-PD-RELATIONSHIP OF APOMORPHINE IN PATIENTS WITH PARKINSONS-DISEASE, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 77-77
Authors:
HARDER S
BAAS H
BERGEMANN N
DEMISCH L
RIETBROCK S
Citation: S. Harder et al., CONCENTRATION-EFFECT RELATIONSHIP OF LEVODOPA IN PATIENTS WITH PARKINSONS-DISEASE AFTER ORAL-ADMINISTRATION OF AN IMMEDIATE-RELEASE AND A CONTROLLED-RELEASE FORMULATION, British journal of clinical pharmacology, 39(1), 1995, pp. 39-44
Authors:
BAAS H
HARDER S
DEMISCH L
BURKLIN F
STECKER K
FISCHER PA
Citation: H. Baas et al., FLUCTUATIONS IN PARKINSONS-DISEASE - PATHOGENETIC SIGNIFICANCE OF LEVODOPAS CEREBRAL PHARMACOKINETICS AND PHARMACODYNAMICS, Journal of neural transmission. Supplementum, (46), 1995, pp. 367-379
Citation: S. Harder et al., PK PD-RELATIONSHIP OF LEVODOPA ALONE AND UNDER APOMORPHINE IN PATIENTS WITH PARKINSONS-DISEASE/, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 145-145
Citation: T. Rommel et L. Demisch, INFLUENCE OF CHRONIC BETA-ADRENOCEPTOR BLOCKER TREATMENT ON MELATONINSECRETION AND SLEEP QUALITY IN PATIENTS WITH ESSENTIAL-HYPERTENSION, Journal of neural transmission, 95(1), 1994, pp. 39-48
Citation: M. Ott et al., INTERLEUKIN-2, SOLUBLE INTERLEUKIN-2-RECEPTOR, NEOPTERIN, L-TRYPTOPHAN AND BETA-2-MICROGLOBULIN LEVELS IN CSF AND SERUM OF PATIENTS WITH RELAPSING-REMITTING OR CHRONIC-PROGRESSIVE MULTIPLE-SCLEROSIS, Journal of neurology, 241(2), 1993, pp. 108-114
Authors:
BAAS H
DEMISCH L
MAUL F
BURKLIN F
HARDER S
FISCHER PA
Citation: H. Baas et al., IMPROVEMENT OF DELAYED GASTRIC-EMPTYING AND ABERRATIC L-DOPA RESORPTION BY DOMPERIDONE IN PARKINSONISM, Neurology, 43(4), 1993, pp. 196-197